Which retatrutide dosage amounts were studied?

What do the study amounts mean for you?

Researchers gave retatrutide as one shot each week, with amounts from 0.5 mg to 12 mg. Each shot went into tissue just below the skin. Those study amounts were not chosen for you.

Retatrutide isn't approved, so the FDA has set no dose, range, or prescription label. After 6 days, about half of the drug was still present in blood. That slow fall explains why researchers used a weekly schedule.

This page links every study amount with its result. You won't find steps for raising an amount or mixing a vial, and it doesn't guide outside use. No figure on this page is personal care advice for you.

Which retatrutide dosage was used in each study?

The first human study, published in 2022: This small early study was called Phase 1b and followed 72 adults with type 2 diabetes for 12 weeks. Staff gave one shot a week into tissue below the skin. Some groups received 0.5 mg, 1.5 mg, or 3 mg. Others moved through 3/6 mg or 3/6/9/12 mg in steps ^[4]. Each slash marks the next step. After 6 days, blood held about half as much of the drug.

The obesity study at stage 2, published in 2023: It followed 338 adults for 48 weeks. They had obesity or excess weight with another health problem. Separate groups received 1 mg, 4 mg, 8 mg, or 12 mg through one shot a week below the skin ^[1]. At 12 mg and 48 weeks, average weight fell 24.2%, compared with 2.1% after placebo.

The diabetes study at stage 2, published in 2023: It followed 281 adults with type 2 diabetes for 36 weeks. Weekly shots below the skin rose in steps from 0.5 mg to 12 mg ^[2]. Researchers checked blood sugar at 24 weeks and weight at 36 weeks. These group plans don't choose an amount for you.

How long does retatrutide stay in your blood?

In 2022, the small Phase 1b study found that about half of retatrutide remained after 6 days ^[4]. Your own fullness hormone, called GLP-1, and another gut hormone last only minutes. Retatrutide lasts longer because a lab-added fat tail holds onto albumin. Albumin is one of the main blood proteins, and holding it helps the drug leave blood slowly.

The 6-day finding has three results:

• One shot each week kept the amount in blood fairly steady.
• Once shots stopped, several weeks passed before the drug left.
• Weekly shots let the amount settle after about 4-5 weeks.

Published work covers only shots into tissue below the skin. Researchers didn't test a pill, nose spray, or shot into a vein. You therefore can't assume that another form would act the same way.

Why doesn't this page explain mixing retatrutide powder?

This site doesn't give steps for mixing retatrutide bought outside a study. No approved vial or mixing guide exists, and a mistake with an injected drug can cause serious harm.

Study staff received retatrutide already mixed in ready-to-use vials. The maker prepared those vials under strict drug rules, so people in the studies didn't mix the drug themselves.

Published work covers the study vial and one shot a week into tissue below the skin. It sets no approved form, mixing method, or storage rule for any other vial. A product bought elsewhere may not match what researchers used.

Powder marked “for research” would need a germ-free liquid before a shot. Its identity, strength, and cleanliness aren't assured. Sellers have received FDA warnings about such vials. We explain that risk but leave out steps for preparing an unapproved shot.

What changed as study amounts rose?

In the stage 2 studies, weight loss and unwanted effects both grew as amounts rose. These obesity-study figures describe groups, so they can't forecast your own result.

Stage 2 weight change at 48 weeks ^[1]:

• 1 mg: the smallest loss of the four amounts
• 4 mg: more loss than the lowest amount
• 8 mg: a large loss compared with placebo
• 12 mg: 24.2% average loss, compared with 2.1% for placebo

Stomach and bowel trouble also grew more common with each rise. Nausea affected up to 45% at the highest amount ^[1]. At the top amounts, pulse climbed about 5-7 beats per minute and peaked near week 24 ^[1]. More weight loss did not mean less risk for you.

A 2024 review linked larger stage 2 amounts with larger changes ^[7]. Weight, blood sugar, blood-fat readings, and blood pressure all moved more. The review doesn't make any study amount an approved dose for you.